CAR-T treatment for hematologic cancer expressing the CD19

AT101 is a type of immunotherapy developed using CAR-T technology for the treatment of blood cancers expressing CD19

  • aAT101
  • AbClon utilized the NEST discovery platform to derive a unique humanized antibody
    (compared to conventional antibodies targeting the FMC63 site of CD19). Our antibody
    with its unique mode of action demonstrates stronger therapeutic effects compared to
    existing CAR-T treatments and represents a new hope for patients who do not respond
    to current FMC63-based CAR-T treatments.

AT101 Anticancer Efficacy

Day No treat T cell CAR-T cell
7 days
14 days
20 days
28 days
© AbClon. All rights reserved.